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Background. We investigated low-dose aspirin (ASA) efficacy and safety in subjects with silent brain infarcts (SBIs) in preventing
new cerebrovascular (CVD) events as well as cognitive impairment. Methods. We included subjects aged ≥45 years, with at least
one SBI and no previous CVD. Subjects were followed up to 4 years assessing CVD and SBI incidence as primary endpoint and as
secondary endpoints: (a) cardiovascular and adverse events and (b) cognitive impairment. Results.Thirty-six subjects received ASA
while 47 were untreated. Primary endpoint occurred in 9 controls (19.1%) versus 2 (5.6%) in the ASA group (p=0.10). Secondary
endpoints did not differ in the two groups. Only baseline leukoaraiosis predicts primary [OR 5.4 (95%CI 1.3-22.9, p=0.022)] and
secondary endpoint-a [3.2 (95%CI 1.1-9.6, p=0.040)] occurrence. Conclusions. These data show an increase of new CVD events
in the untreated group. Despite the study limitations, SBI seems to be a negative prognostic factor and ASA preventive treatment
might improve SBI prognosis. EU Clinical trial is registered with EudraCT Number: 2005-000996-16; Sponsor Protocol Number:
694/30.06.04.
1. Introduction
The importance of early recognition of silent brain infarcts
(SBIs), defined as cerebral ischemic lesions without overt
clinical presentation [1], has been progressively recognized
in the last years. SBIs increase the risk of stroke up to
four times [2–6] in general population. The presence of
SBIs increased the risk of stroke recurrence also in patients
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with symptomatic ischemic brain infarction, compared to
stroke patients without SBIs [6]. Furthermore, the presence
of SBIs more than doubles the risk of dementia, including
Alzheimer’s disease [3], and is associated with a higher
conversion from mild impairment to dementia [3, 5].
Accordingly, it seems appropriate to apply secondary
stroke prevention strategies, instead of those of primary
prevention, in healthy individuals found to have SBIs [7].
The revised guidelines from the American Heart Associa-
tion/American Stroke Association have begun to consider
SBIs as “an entry point for secondary stroke prevention and
an event to be prevented” [8]. Among the modifiable risk
factors, a careful control of arterial hypertension, particularly
nocturnal pattern alteration andmorning surge, is important
for SBIs prevention [9, 10]. Evidence from the Northern
Manhattan study shows that also increased levels of physical
activity are associatedwith a lower risk of SBIs [11]. Nowadays
there is no solid evidence to consider the presence of SBIs per
se as an indication for antiplatelet therapy in healthy people
with SBIs due to the lack of direct trials [7]. Thus, data on
long-term treatment with aspirin (ASA) in healthy people
with SBIs for the prevention of new cardiovascular events are
urgently needed.
The aim of the present study was to assess, in a population
of healthy subjects with SBIs: (i) as a primary endpoint,
the effect of ASA on the incidence of SBIs, stroke, and
transient ischemic attack (TIA); (ii) as secondary endpoints:
(a) the efficacy and tolerability of ASA in the prevention of
cardiovascular events as a combined endpoint of totalmortal-
ity, cardiovascular mortality, nonfatal myocardial infarction
(MI), nonfatal stroke, TIA, and SBIs; (b) the incidence of
cognitive impairment and the effect of ASA therapy on
possible development of cognitive impairment.
2. Materials and Methods
This longitudinal, randomised, double blind controlled ver-
sus placebo study was conducted in eight Italian centres. All
consecutive subjects attending the neurological clinic, aged
≥45 years old, who presented at least one SBI at Magnetic
Resonance Imaging (MRI) were enrolled.
Exclusion criteria were as follows: (i) presence of stroke
or TIA; (ii) contraindication to ASA use; (iii) presence of
microbleeds; (iv) indication to anticoagulant therapy; (v)
malignant arterial hypertension; (vi) cardiac heart failure
(IV class NYHA), (vii) haemoglobin value ≤8g/dl; (viii)
platelet count <100.000; (ix) haemorrhagic disorders; (x)
ongoing antiplatelet or anticoagulant therapy; (xi) serious
inter-current illness.
At baseline, subjects underwent a complete and stan-
dardized vascular screening as well as a neuropsycholog-
ical assessment. Patients were randomized to receive one
of two treatments: (a) ASA 100 mg, administered as an
enteric-coated white tablet, or (b) placebo, an enteric-coated
white tablet with identical appearance. Treatment allocation
remained blinded to investigators and subjects until the
conclusion of the study, except for patients who withdraw for
any collateral or adverse effect and/or any new cardiovascular
events.
Treatment to control vascular risk factors was admin-
istered to all eligible patients at the screening visit and
throughout the study, in accordancewith international guide-
lines [8].
A group of patients were not enrolled in the study because
they refused to participate in the pharmacological trial.These
subjects were studied prospectively and underwent the same
baseline screening and flow chart of exams of those who were
randomized.
After the inclusion in the study, all patients were followed
for four years and also the ones who dropped-out for any
reason except for consensus withdrawal. The annual follow-
up included the following: standardized MRI, neuropsycho-
logical assessment, blood test, and clinical evaluation. At
baseline, at 24 and 48months, an extracranial carotid duplex,
transcranial Doppler, and transcranial colour duplex were
performed.
2.1. MRI Protocol for Diagnosis of SBIs. At admission, all
participants underwent a brain 1.5-Tesla MRI with a stan-
dardised protocol for all centres, as previously described
[12]. They were positioned comfortably so as to avoid even
minimal movements of the head. A scout in the three
spatial plans was performed, positioning the sagittal scans
on the median line, providing a better visualization of
the corpus callosum. Scans have been positioned on axial
plane, parallel to the lower margin of the corpus callosum,
exploring the whole brain. The following sequences were
performed (1-2 acquisitions for each sequence): diffusion-
weighted imaging (DWI); TSE double-echo T2 weighted
(Proton density-T2) (TR 2000-4500, TE 15-50/80-120); f-
FLAIR (TR 7000-11000, TE 150/200, TI 1500-2000, Echo-
train-length 30-50); gradient-echo (FFE-FLASH) (TR 600-
800, TE 20-30, Flip angle 15-25); and three-dimesional-T1
(SPGR or MPRAGE) (TR 20-30, TE 5-10, Flip angle 50). For
all scans, the same number of slices were obtained using the
following parameters: 44-48 slices of the thickness of 3 mm
(gap: 0mm), FOV 25 cm,matrix 256 x 256, and L/R direction
of coding phase.
SBIs were defined as focal hyperintensity on T2-weighted
images, 3 mm in size or larger as described by Vermeer
and collaborators [2]. Proton-density sequence was used
to distinguish infarcts from dilated perivascular spaces.
Infarct lesions in the white matter were distinguished from
white matter lesions by corresponding hypointensity on T1-
weighted images.
A neuroradiologist, blinded to the patient’s medical his-
tory, classified SBIs according to size and location. Cortical
and subcortical atrophy and leukoaraiosis were evaluated
and scored as absent or present. A good “inter-intra-rate
reliability” (k=0.70) among three expert neuroradiologists
was reached before starting the study enrolment (P.P., F.F., and
S.B.).
An experienced neurologist, blinded to MRI results,
reviewed the medical history to exclude any previous cere-
brovascular overt episode. Finally, medical history and imag-
ing data were matched in order to categorize the infarct as
silent or symptomatic.
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2.2. Evaluation of Cognitive Performance. The neuropsycho-
logical evaluation was assessed by de Groot and colleagues’
method [13] due to its sensitivity to subcortical dysfunction
[14]. Three domains were explored: speed of cognitive pro-
cesses, memory function, and global cognitive function [14].
To evaluate speed ofmental processes, we used the Stroop
test, the Paper-and-PencilMemory ScanningTask, the Letter-
Digit Substitution Task, and a verbal fluency test. Memory
function was evaluated by a 15-word verbal learning test. As
measures of global cognitive function, we used a combination
of the above-mentioned tests as well as theMini-mental State
Examination (MMSE).
2.3. Clinical Assessment. We recorded (i) demographic data
(sex, age, Body Mass Index [BMI], and education level); (ii)
vascular risk factors and related treatments (arterial hyper-
tension, diabetes mellitus, hypercholesterolemia, hyper-
triglyceridemia, current and previous smoking habit, alco-
hol consumption, hyperhomocysteinemia, internal carotid
artery stenosis >50% of the lumen, and intima-media thick-
ness); (iii) medical history (MI, atrial fibrillation [AF], heart
failure, metabolic syndrome, ongoing oral anticoagulant or
antiplatelet therapy, andmigrainewith andwithout aura); (iv)
baseline vital signs (systolic and diastolic blood pressure and
temperature).
2.4. Endpoints. The primary criterion was a combined end-
point of ischemic stroke (IS), TIA, and new SBIs detected
at MRI. The evaluation was performed by considering the
number of new SBIs occurring during the study, calculated as
the difference between lesions at endpoint and baseline MRI.
Any TIA or IS occurrence was added to this computation.
The secondary criterion was assessed by (a) the incidence
of new cardiovascular events (combined endpoint of total
mortality, cardiovascular mortality, nonfatal MI, nonfatal IS,
and TIA) and SBIs and the count of adverse events; (b) the
eventual cognitive decline. Adverse events were classified
among serious or not serious, expected or unexpected, and
categorized.The incidence of haemorrhagic stroke andmajor
bleeding of gastrointestinal tract was calculated separately.
2.5. Statistics. In order to improve the statistical power of
the study, subjects who participate to pharmacological trial
were analysed together with those who participate in the
observational study.All subjectswere divided into two groups
according to their decision of starting or not ASA therapy:
ASA versus controls (placebo or no therapy).
Descriptive statistics are reported as count and percent-
age. Categorical data were evaluated with the Chi-square or
the Fisher exact test as appropriate. Two predictive models
were carried out to assess any potential prognostic factor
of new SBIs, stroke, TIA (primary endpoint), or all car-
diovascular and adverse events (secondary endpoints). The
predictive models have been assessed using the multivariable
logistic regression with a forward approach. Results are
presented asOdds Ratios (OR) and 95%Confidence Intervals
(CI). The predictive models’ goodness of fit was tested with
the Hosmer-Lemeshow test. Area under the Curve (AUC)
values were assessed for each significant variable and the full
models. Models sensitivity, specificity, and predictive values
were given. Psychomotor speed, memory performance, and
cognitive indexes were obtained according to De Groot and
colleagues [13]. These scores were compared both transver-
sally and longitudinally using the Wilcoxon Mann-Whitney
test and the repeated-measures ANOVA (ANOVARM).
ANOVARM models accounted for both between and within
sources of variability, using mixed effect models. Effects
tested were treatment (2 levels: ASA and controls), visit (5
levels: 0, 12, 24, 36, and 48 months), and the interaction
between treatment and visit. All analyses were carried out
on an Intent-to-Treat (ITT) population. Analyses pertaining
the cognitive evaluation were applied on (1) observed data
(no imputation) and (2) last observation carried forward
(LOCF) datasets.TheANOVARM analyses conducted on the
observed data dataset were adjusted for missing evaluations
using the pattern mixture model. All tests were two-tailed
with significance set to alpha=0.05 and CI =95%. Data were
analysed using the Statistical Analysis System (SAS Institute,
Inc., Cary, NC, U.S.A.) package for PC (version 9.2) and
Statistical Package for the Social Sciences (SPSS) package for
Windows (version 20.0).
Given the low statistical power of the study, a parallel
Bayesian analysis was performed on the primary outcome
and MI occurrence (composite vascular endpoint) at 1 year
for the 50 subjects who were included in the pharma-
cological trial. We used the Gibbs sampling (a Markov
Chain Monte Carlo MCMC algorithm) for obtaining a
sequence of random samples (1000) from the multivari-
ate probability distribution and from the joint probability
distribution of the uninformative prior and the binomial
distribution (successes and failures occurrence) of the data
observed.
2.6. Ethics. The study was approved by the local Ethics
Committee (EUClinical trial registration: EudraCTNumber:
2005-000996-16; Sponsor Protocol Number: 694/30.06.04).
The procedures described in the study according to con-
duction, evaluation, and documentation were conceived in
conformity to Good Clinical Practice Guidelines and were
inspired by the principles of the Declaration of Helsinki
(1964) and its later amendments. All participants to the study
signed a written informed consent.
3. Results
3.1. General Features. During the study period, 350 subjects
underwent the baseline screening procedure. At the end, 124
subjects were recruited. Forty-one subjects were excluded
after central neuroradiological diagnosis review. Fifty sub-
jects were enrolled in the double-blind study (14 in Perugia,
12 in Roma, 7 in Pavia, 6 in Ancona, 6 in Bari, 1 in Firenze,
1 in Imperia, and 3 in L’Aquila). Out of 50, 24 subjects were
randomized toASA treatment and 26 to placebo.Thirty-three
subjects (24 in Roma, 4 in Ancona, 4 in L’Aquila, and 1 in
Perugia) were studied prospectively but they did not enter the
study because refused to participate in the pharmacological
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trial. Out of 33, 12 subjects underwent treatment with ASA
and 21 with no ASA.
3.2. Main Characteristics of the Study Population. The
demographical and clinical characteristics of the subjects
underwent treatment with ASA and controls are reported
in Table 1. Only treatment with Angiotensin-Converting-
Enzyme inhibitors resulted in being unbalanced in the two
groups (p=0.001). Although significance was not reached, a
slight positive trend was observed in control group than in
ASAgroup for greater occurrence of arterial hypertension (29
[61.7%] versus 17 [47.2%] patients, p=0.077, respectively) as
well as hyperhomocysteinemia (12 [25.5%] versus 6 [16.7%]
patients, p=0.188, respectively).
3.3. Primary Endpoint. The number and rates of primary
endpoint occurrences were reported in Table 2. Although
significance was not reached (p=0.103), there were 9 (19.1%)
versus 2 (5.6%) cerebrovascular events and new SBIs events
in the control and ASA arms, respectively.
3.4. Secondary Endpoint-a. All cardiovascular events
occurred in the ASA and control groups during the four
years of observation are reported in Table 3. The only,
nonsignificant, imbalance was on the primary endpoint,
in fact other cardiovascular events (nonfatal MI, all
cardiovascular mortality) are fairly balanced 5.6% and 4.2%,
respectively, in the ASA and the control groups. Also adverse
events are fairly balanced in two groups 5.6% and 4.2%,
respectively, in the ASA and the control groups (see Table 3).
All events that led to discontinuation of the treatment are
resumed in Table 4. During the study period, two control
participants started aspirin and two participants in the ASA
group stopped aspirin because of gastrointestinal adverse
events.
3.5. Logistic Regression Analyses. All demographical and
clinical variables reported in Table 1 were then correlated
with the primary (model A) and secondary (model B)
endpoints with two multivariable logistic models using the
forward approach. The only variable retained significance in
both model A (primary endpoint) and model B (secondary
endpoint) was leukoaraiosis, with OR 5.4 (95%CI 1.3-22.9),
p=0.022 and OR 3.2 (95%CI 1.1-9.6), p=0.040, respectively.
Model A was almost discretely predictive (AUC=0.697)
with a sensitivity of 72.7%, specificity of 66.7%; positive and
negative predictive value of 25.0% and 92.3%, respectively.
Conversely, model B was modestly predictive (AUC=0.644),
with a sensitivity of 61.1%, specificity of 67.7%, and positive
andnegative predictive value of 34.4%and 86.3% respectively.
3.6. Secondary Endpoint-b. Changes (Δ) in psychomotor
speed, memory performance, and global cognitive indexes
between the last and the first visit after assignment to the
drug for both ITT and completer populations were reported
in Table 5. No significant differences between groups were
detected.
ANOVARM model’s results are reported in Table 6. The
effect of “treatment” and the interaction between “treatment”
and “visit” were nonsignificant in each model performed.
3.7. Bayesian Analysis on the Composite Vascular Endpoint.
An exploratory Bayesian analysis was performed excluding
the nonrandomized patients to increase the power of the
analysis. The data at the end of the first year only were con-
sidered in this analysis because almost all patients completed
follow-up at this time point. According to 1000 simulations
there was a 96.3% chance of achieving higher failure rates
on the composite vascular endpoint (primary endpoint + MI
occurrence) with placebo with a 95% chance the difference
in the proportion of failure between placebo and ASA falling
in the range (+38.0%, -1.4%) and a median value of +15.2%
(Table 7). In practice for 963 samples of the 1000 simulated,
the number of placebo failures was greater than the number
of ASA failures (Table 7).
4. Discussion
Our study has shown that (i) although significance was not
reached, an increase of newCVD events in controls occurred,
(ii) there was no difference in tolerability between ASA and
control group, (iii) presence of leukoaraiosis at baseline was
independently associated with the occurrence of primary
and secondary endpoints, and (iv) there was no significant
difference in incidence of cognitive impairment betweenASA
and control group during the follow-up.
The strengths of our study were (i) prospectively multi-
centre data collection, with a homogeneous and aggressive
preventive vascular treatment, (ii) use of strict radiological
and clinical inclusion criteria, and (iii) central reading of
neuroimaging, so as to avoid diagnostic bias. Indeed, the
variation inMRI characteristics and imaging criteria for SBIs
diagnosis may partially account for discrepancies in various
studies and consequently SBIs detection [5, 15]. A meta-
analysis on radiological criteria for SBIs diagnosis has under-
lined that, in half of studies published, SBIs were defined
simply as hypointense area on T1 scans and hyperintense
area on T2-weighted images sized ≥3 mm, not considering
exclusion criteria for dilated Virchow-Robin spaces, leading
to a consequently possible overestimation of SBIs preva-
lence [15]. Moreover, considering the established association
between vascular risk factors and SBIs [1], the homogeneous
treatment of all subjects in terms of vascular prevention
allowedminimizing their possible role in CVD incidence and
better evaluating the role of antithrombotic therapy.
The major limit of our study is the small size of pop-
ulation, mainly due to (i) the enrolment method since
subjects spontaneously came to clinical observation for
other reasons (mainly headache or nonspecific dizziness),
(ii) strict inclusion criteria, and (iii) the consent to ran-
domization. Indeed, randomization was often hindered by
general practitioners who preferred to prescribe directly ASA
treatment. Although data to guide management of patients
with silent infarction are limited, the guideline American
Heart Association/American Stroke Association summarizes
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Table 1: Baseline demographical and clinical characteristics of the study population (n=83) and bivariate comparison between patients
treated and not treated. ∗Value given as median (interquartile range). All other data are reported as absolute number of subjects (%).
ASA Controls p value
n=36 n=47
Demographic characteristics
Female sex 24 (66.7) 33 (70.2) 0.730
Age∗ 66 (54-72) 68 (60-73) 0.429
Education ≥9 years 11 (32.4) 18 (42.9) 0.582
Body Mass Index 0.551
25-30 18 (50.0) 13 (27.6)
≥30 6 (16.7) 9 (19.1)
Risk factors
Arterial hypertension 17 (47.2) 29 (61.7) 0.188
Diabetes mellitus 1 (2.8) 1 (2.1) 1.000
Hypercholesterolemia 26 (72.2) 29 (61.7) 0.315
Hypertriglyceridemia 8 (22.2) 5 (10.6) 0.150
Current smoking 6 (16.7) 7 (14.9) 0.826
Previous smoking habit 11 (30.6) 10 (21.3) 0.335
Excessive Alcohol consumption 9 (25.0) 11 (23.4) 0.866
Hyperhomocysteinemia 6 (16.7) 12 (25.5) 0.077
Carotid atheroma 3 (8.3) 1 (2.1) 0.312
Medical history
History of atrial fibrillation 1 (2.8) - 0.434
Ischemic Heart Disease 1 (2.8) - 0.434
Heart failure - - -
Migraine with aura 4 (11.1) 2 (4.3) 0.396
Migraine without aura 7 (19.4) 12 (25.5) 0.513
Treatments
Statins 6 (16.7) 7 (14.9) 0.826
Fibrate 1 (2.8) - 0.434
ACE inhibitors 13 (36.1) 3 (6.4) 0.001
ARB 6 (16.7) 15 (31.9) 0.113
Beta-blockers 6 (16.7) 5 (10.6) 0.422
Calcium channel blockers 3 (8.3) 10 (21.3) 0.135
Diuretics 8 (22.2) 11 (23.4) 0.899
Anti-arrhythmic - 1 (2.1) 1.000
Oral hypoglycaemic - 2 (4.3) 0.503
Insulin - - -
Nitrated 2 (5.6) - 0.185
Lesion location
Basal ganglia 5 (13.9) 11 (23.4) 0.276
Cerebellum 2 (5.6) 2 (4.3) 1.000
Brainstem 3 (8.3) 10 (21.3) 0.135
Sub-cortical 29 (80.6) 39 (83.0) 0.776
Peri-ventricular 23 (63.9) 32 (68.1) 0.689
Leukoaraiosis 12 (33.3) 19 (40.4) 0.508
Cortical atrophy 12 (33.3) 12 (25.5) 0.437
Sub-cortical atrophy 10 (27.8) 6 (12.8) 0.086
Right side 31 (86.1) 43 (91.5) 0.492
Left side 34 (94.4) 4 (89.4) 0.693
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Table 1: Continued.
ASA Controls p value
n=36 n=47
Cognitive and behavioural tests
ADL score∗ 6 (6-6) 6 (6-6) 0.862
IADL score∗ 8 (8-8) 8 (8-8) 0.134
MMSE score∗ 29 (27-30) 29 (27-30) 0.874
BDI score∗ 3,5 (1,75-7) 5 (1-7) 0.917
HDRS score∗ 11 (14-15,5) 13 (9-14,5) 0.284
MADRS score∗ 6 (2,5-10,5) 8 (3-12,5) 0.299
IQ-code score∗ 81 (78,5-85,5) 81,5 (79-87) 0.476
ACE inhibitors: Angiotensin-Converting-Enzyme inhibitors; ARB: Angiotensin-Receptor Blockers; ADL: Activities of Daily Living; IADL: Instrumental
Activities of Daily Living; MMSE: Mini-Mental State Examination; BDI: Beck Depression Inventory; HDRS: Hamilton Depression rating Scale; MADRS:
Montgomery-Asberg Depression Rating Scale; IQ-code: Informant Questionnaire on Cognitive Decline in the Elderly.
Table 2: Primary endpoint occurrences.
ASA n=36 controls n=47
n (%) n (%) p-value (Fisher Exact)
New SBIs 1 (2.8) 6 (12.8)
0.103Stroke 1 (2.8) 2 (4.3)
TIA - 1 (2.1)
No CV events 34 (94.4) 38 (80.9)
Table 3: Secondary endpoint-a occurrences (all cardiovascular





n (%) n (%) p-value(Chi-Square)
Non-fatal stroke 1 (2.8) 1 (2.1)
0.331
TIA - 1 (2.1)
New SBIs 1 (2.8) 6 (12.8)
Non-fatal MI 2 (5.6) 1 (2.1)
CVmortality - 1 (2.1)
Gastrointestinal adverse
events 2 (5.6) 1 (2.1)
Epistaxis - 1 (2.1)
Other causes of mortality - -
No events 30 (83.3) 35 (74.5)
these data where they could be found and incorporate them
into relevant sections of this guidelines [8]. Nevertheless,
antithrombotic therapy in subjects with SBIs is still to be
supported by clinical trials [7, 16].
Despite the small size of our population, ASA therapy
could ameliorate SBIs prognosis on CVD. This finding is
in line with other trials investigating the preventive effect
of antithrombotic agents. Two small randomised controlled
Japanese trials examining SBIs as a surrogate endpoint have
been carried out in selected diabetic population, mostly free
of SBIs at baseline, treated with either the antithrombotic
agents cilostazol [17] or dilazep hydrochloride [18]. Both trials
Table 4: Number and rates of secondary endpoints, tolerability and
drop out occurrences during the trial.
ASA n=36 controls n=47
n (%) n (%)
Primary endpoint 2 (5.6) 9 (19.1)
Other cardiovascular events 2 (5.6) 1 (2.1)
Adverse events 2 (5.6) 2 (4.2)
Switch ASA - 2 (4.2)
Lost to follow-up 9 (25.0) 9 (19.1)
Mortality - 1 (2.1)
Low compliance 2 (5.6) -
Withdraws consent 4 (11.1) -
Completed follow-up 15 (41.7) 23 (48.9)
found that the incidence of SBIs was significantly lower in
the drug-treated group than in the control group. In patients
with nonvalvular AF, aspirin was found to reduce SBIs [19],
while anticoagulant therapy did not affect the rate of SBIs in
the SPINAF study [20]. If ASA preventive treatment might
contribute to ameliorate SBI, prognosis will be better clarified
by ongoing trials as ASPREE study [21] and its substudy
ENVIS-ion [22] aims to determine if a low dose of aspirin
may prevent death and disability, including cognitive decline,
and reduce the development of white matter hyperintense
lesions and SBIs as assessed by MRI in elderly, as well [22].
Furthermore, we observed a trend towards a greater
occurrence of arterial hypertension and hyperhomocysteine-
mia in controls than in ASA group. Despite the lack of
statistically significant differences between the two groups,
we cannot exclude that this might slightly bias our results.
Baseline characteristics of our study population con-
firmed the strong association between SBIs and arterial
hypertension [1, 23] and, to lesser extent, hypercholes-
terolemia [1]. Indeed, more than half and around two-thirds
of population at baseline were affected by arterial hyperten-
sion and hypercholesterolemia, respectively. On the other
hand, only few subjects presented hyperhomocysteinemia
[1, 23] and smoking habit [1], also found to be associated with
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Table 5: Secondary endpoint-b: change (last follow-up versus baseline) in cognitive indexes.
ASA controls p-value
Change in the Psychomotor speed score
LOCF Δ (last-first) Mean (SD) -0.03 (0.17) -0.04 (0.54) 0.3205
NON IMPUTED Δ (last-first) Mean (SD) 0.07 (0.05) 0.19 (0.99) 0.3082
Change in the Memory performance score
LOCF Δ (last-first) Mean (SD) -0.29 (0.61) -0.08 (0.74) 0.2238
NON IMPUTED Δ (last-first) Mean (SD) 0.14 (0.41) -0.08 (0.91) 0.3747
Change in the Global cognitive index score
LOCF Δ (last-first) Mean (SD) -0.20 (0.46) -0.12 (0.51) 0.2507
NON IMPUTED Δ (last-first) Mean (SD) -0.07 (0.34) -0.03 (0.61) 0.8353
Table 6: ANOVARMmodels on cognitive domains.
Treatment Visit Treatment∗Visit
p-value p-value p-value
Psychomotor speed Non imputed 0.1776 0.3640 0.0976
LOCF 0.2523 0.6886 0.6286
Memory performance Non imputed 0.3744 0.0603 0.8072
LOCF 0.6512 0.0011 0.3446
Global cognitive index Non imputed 0.8449 0.1548 0.9128
LOCF 0.9332 <0.0001 0.8932
General cognitive
evaluation
Non imputed 0.6969 0.3913 0.5367
LOCF 0.9861 0.0201 0.3556
Episodic memory Non imputed 0.9032 0.3466 0.6365
LOCF 0.4948 0.0967 0.3351
Short-termmemory Non imputed 0.2731 0.9264 0.9663
LOCF 0.4543 0.9630 0.5808
Executive functions Non imputed 0.8123 0.6211 0.5504
LOCF 0.0952 0.8617 0.4169
Language Non imputed 0.2712 0.9891 0.9413
LOCF 0.6422 0.7070 0.8942
Problem solving Non imputed 0.7387 0.7072 0.3618
LOCF 0.8405 0.0224 0.0677
Dementia staging Non imputed 0.5226 0.1699 0.5337
LOCF 0.6445 0.7873 0.4778
Daily living activities Non imputed 0.4063 0.9233 0.9826
LOCF 0.1288 0.9979 0.3036
Major psychiatric
disorders
Non imputed 0.1139 0.3879 0.1515
LOCF 0.1028 0.0079 0.4263
Table 7: Bayesian analysis on the primary outcome + MI.
Bayesian analysis
Quantiles
1.0% 2.5% 5.0% 25.0% 50.0% 75.0% 95.0% 97.5% 99.0%
% of (placebo failures-ASA failures) +38.0% +34.2% +31. 0% +21.4% +15.2% +9.4% +1.3% -1.4% -4.8%
Light face values=ASA better than placebo. Italic values=placebo better than ASA.
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SBIs, and others risk factors associated with symptomatic
lacunar infarction as diabetes and ischemic heart disease
[23].
The vast majority of SBIs is small and deep and reflects
penetrating artery disease, a pathogenesis shared with lacu-
nar infarcts. Ischaemic leukoaraiosis, or white matter hyper-
intensities, is thought to be, together with lacunar infarction,
different form of small vessel disease [24]. The presence and
extent of leukoaraiosis represent a radiological marker of
small vessel disease and an important predictor of first-ever
and recurrent stroke, cognitive impairment, and functional
disability [25]. It is recently used as surrogate endpoint
in CVD clinical trials [26]. In our study, the presence
of leukoaraiosis is associated with primary and, to lesser
extent, secondary endpoint. This finding might confirm the
belonging of leukoaraiosis and SBIs to the same spectrum
of pathology, possibly being different temporal stages of the
same pathology [27, 28]. The brain mapping in patients with
leukoaraiosis showed that tiny clinically silent acute infarcts
occur in these patients [27].The radiological characteristic of
these lesions became similar to characteristics of preexisting
leukoaraiosis over time, suggesting that the accumulation of
SBIs could be one of the most important, if not the primary
cause of leukoaraiosis [27].
In our population, there was no significant difference
in the incidence of cognitive impairment between patients
treated and not during the 4-year follow-up. The presence of
SBIs is known to be associated with a 2-fold risk of dementia,
a steeper decline in age-associated cognitive function and
a higher conversion from mild impairment to dementia
[3, 5]. The question of whether low-dose aspirin might be
protective against cognitive decline remains unanswered [29,
30]. Possible explanations of the lack of long-term aspirin
treatment effect in our population could be (i) the relative
young age (median of 66 years in the ASA group versus 68
years in the control group), (ii) the relative short-term follow-
up, and (iii) the strict control during all the follow-up of
vascular risk factors, emerged as important contributors to
the development of Alzheimer’s disease.
The general practitioners’ attitude to treat in secondary
prevention healthy subjects with SBIs in daily clinical practice
has preceded of some years the experts’ agreement. In
fact, recently American Heart Association/American Stroke
Association guidelines reported SBIs as an important and
emerging issue in secondary stroke prevention.
Despite the fact that larger randomized studies are needed
to confirm these findings in subjects with silent brain infarcts,
these results may suggest that subjects with SBI are at risk of
cardiovascular events and benefit from secondary prevention
therapy. A further observation emerging from this study
is that also subjects with mild leukoaraiosis are at risk of
cardiovascular events and probably have to be treated in
secondary prevention too.These subjects need to be followed
up as well as stroke patients.
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